Calcitonin human-salmon hybrid - Tsumura

Drug Profile

Calcitonin human-salmon hybrid - Tsumura

Alternative Names: TJN 135

Latest Information Update: 22 Aug 2002

Price : $50

At a glance

  • Originator Tsumura
  • Class Osteoporosis therapies
  • Mechanism of Action Calcitonin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 22 Aug 2002 Discontinued - Phase-II for Postmenopausal osteoporosis in Japan (unspecified route)
  • 19 May 1998 New profile
  • 19 May 1998 Phase-II clinical trials for Postmenopausal osteoporosis in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top